This content is machine translated Severe hypoglycemic events in T1D Significantly higher burden – also for the wallet A severe hypoglycemic event (SHE) in adults with type 1 diabetes (T1D) is defined by the need to involve another person for recovery and is associated with, among other things,…
View Post 3 min This content is machine translated Adolescents with type 1 diabetes Metformin can improve subclinical atherosclerosis Neuregulin-4 (Nrg-4) may have anti-inflammatory and anti-atherogenic properties. Egyptian researchers used Nrg-4 together with carotid intima-media thickness as a marker for subclinical atherosclerosis. Their finding: The addition of metformin to…
View Post 4 min This content is machine translated SGLT-2-i in type 2 diabetes and CVD Cardioprotective mechanisms of action of empagliflozin – what’s new? Empagliflozin is known to reduce the risk of atherosclerotic cardiovascular disease (CVD) in people with type 2 diabetes and high cardiovascular risk. The mechanisms underlying these effects are not yet…
View Post 4 min This content is machine translated AID systems for type 1 diabetes New real-world data shows: AI makes the difference In hybrid closed-loop systems, algorithms control the automated insulin delivery (AID). Compared to conventional insulin administration, this not only has a favorable effect on HbA1c values, but also on patient-oriented…
View Post 4 min This content is machine translated Dual GIP/GLP-1 RA in type 2 diabetes Tirzepatide proves multiple benefits In the Phase III SURPASS study program, the dual receptor agonist tirzepatide performed convincingly. The results of several post-hoc analyses are now also available. At the annual meeting of the…
View Post 6 min This content is machine translated Type 2 diabetes: new ADA/EASD consensus report. Holistic treatment with a view to cardiorenal effects. The 2022 position paper of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) proposes to implement a holistic, multimodal treatment approach in the…
View Post 4 min This content is machine translated SUSTAIN-10: Post-hoc analysis Semaglutide and liraglutide in type 2 diabetes: effective and safe with and without SGLT-2-i Based on empirical evidence, professional societies recommend early combination of metformin with an SGLT-2 inhibitor or a GLP-1 receptor agonist in type 2 diabetics. Increasingly, a combined application of the…
View Post 7 min This content is machine translated European Diabetes Congress in Vienna High expectations for new therapeutic options At the EASD congress in Vienna, gliptins, gliflozines and further improved insulins were seen as the great hope in diabetology. But medical technology also presented itself in a good position;…
View Post 9 min This content is machine translated How to treat diabetes? This is how the music of the future sounds Some new drugs and new techniques are expected to improve glycemic control in type 1 and type 2 diabetes. In addition to proper medication selection, a patient-centered approach is essential.…
View Post 4 min This content is machine translated Diabetes “Better care for patients thanks to personalized therapy” Prof. Oliver Schnell, MD, is concerned that more and more people are developing diabetes, which is associated with high morbidity and a reduced quality of life. The diabetologist from Munich…
View Post 3 min This content is machine translated Treatment for resistant hypertension using renal denervation Diabetics could benefit from reduction of sympathetic tone About ten percent of treated hypertensives have high blood pressure that cannot be adequately controlled despite combinations of three or more antihypertensives. These patients may be helped by interrupting sympathetic…
